Research Article

Serum Cystatin C Predicts Mortality in HBV-Related Decompensated Cirrhosis

Table 1

Baseline clinical and laboratory characteristics of the study population.

HBV-DeCi patients (n=75)

Gender (male/female)59/16
Age (y)53.0±11.0
Total protein (g/L)58.8±8.1
Albumin (g/L)28.0±5.2
ALT (U/L)38.0(23.0–66.0)
AST (U/L)56.0(60.0–87.0)
Total bilirubin (μmol/L)96.0(61.0–203.0)
INR1.60±0.39
Serum Cr (mmol/L)72.0(60.0–99.0)
HBsAg, positive75
HBeAg, positive44
HBcAb IgM, positive0
Cystatin C (mg/L)1.06(0.90–1.48)
MELD score17.4(13.7–21.4)
Child-Pugh score10.0(9.0–11.0)
Modes of decompensation10.0(9.0–11.0)
 HE, n (%)2(2.7%)
 HRS, n (%)5(6.7%)
 Ascites, n (%)48(64.0%)
 Variceal bleeding, n (%)22 (29.3%)

Data are expressed as n, mean ± SD, or median (interquartile range).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; Cr, creatinine; HE, hepatic encephalopathy; HRS, hepatorenal syndrome; MELD score, model for end-stage liver disease score.